You need to sign in or sign up before continuing.
The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Randomized Controlled Trial Multicenter Study
NXY-059 for acute ischemic stroke.
NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. ⋯ The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. (ClinicalTrials.gov number, NCT00119626.).